Edition:
United States

People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

50.73USD
11:14am EDT
Change (% chg)

$0.36 (+0.71%)
Prev Close
$50.37
Open
$50.31
Day's High
$50.97
Day's Low
$50.13
Volume
168,389
Avg. Vol
786,940
52-wk High
$63.40
52-wk Low
$41.93

Ehrich, Elliot 

Dr. Elliot W. Ehrich M.D. is Executive Vice President - Research and Development and Chief Medical Officer of the Company. Prior to assuming his current positions, from September 16, 2011 until February 2015, Dr. Ehrich was our Senior Vice President, Research and Development, and Chief Medical Officer. From May 2007 to September 16, 2011, Dr. Ehrich served as Senior Vice President, Research and Development, and Chief Medical Officer of Alkermes, Inc. Prior to this Dr. Ehrich served as Vice President, Science Development and Chief Medical Officer of Alkermes, Inc. Prior to joining Alkermes in 2000, Dr. Ehrich spent seven years at Merck & Co., Inc. (“Merck”), a publicly traded pharmaceutical company, overseeing the clinical development and registration of novel pharmaceuticals. Dr. Ehrich is a Fellow of the American College of Rheumatology and has had numerous publications in peer-reviewed journals. Dr. Ehrich worked as a research associate at the European Molecular Biology Laboratory in Heidelberg, Germany before attending medical school. Dr. Ehrich is also a member of the scientific advisory boards for Aileron Therapeutics and Heptares Therapeutics, both privately held biopharmaceutical companies. Dr. Ehrich is also a strategic advisor to Verge Genomics.

Basic Compensation

Total Annual Compensation, USD 533,704
Restricted Stock Awards, USD 742,210
Long-Term Incentive Plans, USD --
All Other, USD 2,176,290
Fiscal Year Total, USD 3,452,210

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 95,414 3,303,550.00
Name Fiscal Year Total

Richard Pops

9,647,420

Shane Cooke

4,144,870

James Frates

2,678,060

Kathryn Biberstein

3,430,420

Elliot Ehrich

3,452,210

Iain Brown

--
As Of  30 Dec 2016